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PROSPECTIVE STUDY USING R2 MRI DEMONSTRATES HIGH IRON BUR-
DEN IN ALLOGENEIC PEDIATRIC STEM CELL TRANSPLANT RECIPIENTS
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Background: Iron overload has been implicated as a key co-morbid
factor in post-stem cell transplant (SCT) outcomes. Quantifying
iron burden has been a challenge as serum iron markers are impre-
cise. MRI is a relatively new and non-invasive tool that more accu-
rately measures iron burden. We conducted a prospective study
using MRI to assess iron burden in children undergoing SCT.
Objective: To determine the prevalence of iron overload using R2
MRI of the liver in a pediatric allo SCT population both pre and
post-SCT. Relationships between excess iron and adverse outcomes
such as graft vs. host disease (GVHD), infection, and death were sec-
ondary objectives.
Methods: Children$5 years old undergoing an allo SCT at Child-
ren’s Hospital Boston from 2007-2009 were eligible for this study.
Iron overload was defined as a liver iron concentration $ 1.5 mg
iron/g dry liver tissue. A paired t-test was conducted with a 5 0.05
to compare iron load at the two specified time points. A two-sample
two-sided t-test was conducted at each time point for association
with risk factors described above with a 5 0.1. This study was IRB
approved.
Results: Twenty-eight patients were enrolled. The most common
diagnoses were Pre-B ALL (N5 7), AML (N5 6), and aplastic ane-
mia (N 5 5). Pre-SCT, 82% (95% CI: 66% - 98%) of patients had
iron overload by R2MRI. At day 100 post-SCT, 95% (95%CI: 65%
- 100%) had iron overload. The mean iron concentration (6 std er-
ror) was 4.976 3.54 mg/g dwt liver at pre-SCT and 7.556 4.37 mg/
g dwt liver at day 100 post-SCT. The day 100 post-SCTmean value
was significantly higher than the mean value at pre-SCT (2.15 mg/g
dwt liver, p\0.0001). For patients who developed an infection dur-
ing the post-SCT period, the mean iron concentration, compared
to patients who did not develop an infection, was significantly higher
at pre-SCT and at day 100 post-SCT (p5 0.029 and p5 0.0055, re-
spectively). There was no statistically significant difference in iron
concentration between patients who developed GVHD or died
and those who did not.
Conclusions: We found that a high proportion of pediatric allo
SCT patients have iron overload pre-SCT. In addition, there is a sta-
tistically significant rise in iron post-SCT (p\0.0001) and an associ-
ation with increased incidence of infection in patients with elevated
iron. Larger multi-center studies should be conducted to further ex-
amine the consequences of iron overload and evaluate potential in-
terventions in this patient population.273
ALEMTUZUMAB IS AN EFFECTIVE SALVAGE AGENT FOR REFRACTORY
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
Marsh, R.A.1, Filipovich, A.H.1, Allen, C.E.2, McClain, K.L.2,
Weinstein, J.L.3, Kanter Washko, J.4, Skiles, J.5, Lee, N.D.5,
Khan, S.P.6, Lawrence, J.1, Mo, J.Q.7, Bleesing, J.J.1, Jordan, M.B.1,8
1Cincinnati Children’s Hospital; 2Baylor College of Medicine; Texas
Children’s Cancer Center; 3Northwestern University Feinberg School of
Medicine, Children’s Memorial Hospital; 4Tulane Medical Center; 5Riley
Hospital for Children; 6Mayo Clinic; 7Cincinnati Children’s Hospital;
8Cincinnati Children’s Hospital
Background: Familial hemophagocytic lymphohistiocytosis
(FHLH) consists of several genetic disorders that compromise lym-
phocyte cytotoxicity and lead to the life-threatening hyper-inflam-
matory syndrome of HLH. Even with current standard HLH
therapy, only approximately half of patients will experience complete
resolution of disease, andmortality prior to allogeneic hematopoietic
cell transplantation (HCT) remains a significant problem. Salvage
therapies have been described only in limited case reports, and there
are no large studies of second-line therapies.
Methods:We reviewed the charts of 22 pediatric and adult patients
who received alemtuzumab for the treatment of refractory primaryHLH at our center or in consultation with our group. Patients had
received conventional therapies for a median of 8 weeks (range
2-70) prior to alemtuzumab, and treatment immediately prior to
alemtuzumab included dexamethasone (100%), etoposide (77%), cy-
closporine (36%), intrathecal hydrocortisone+/-methotrexate
(23%), methylprednisolone (9%), and rituximab (14%). Patients re-
ceived a median dose of 1mg/kg alemtuzumab (range 0.1-8.9mg/kg)
divided over a median of 4 days (range 2-10).
Results: Nineteen patients (86%) experienced a partial response.
Seventeen patients (77%) survived to undergo allogeneic HCT at
a median of 52 days following first alemtuzumab administration
(range 16-121 days). One additional patient is surviving and not cur-
rently a candidate for HCT. Patients experienced an acceptable
spectrum of complications, including CMV and adenovirus viremia.
All but 1 patient undergoing HCT survived to day +100 following
HCT.
Conclusion: Alemtuzumab is an effective salvage agent for refrac-
tory HLH, leading to disease improvement and survival to HCT
in the majority of patients.274
HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS HEMATOPOIETIC
STEM CELL RESCUE FOR CHILDRENWITH HIGH-RISK NEUROBLASTOMA.
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Neuroblastoma (NB) is the most common extracranial solid tu-
mor in children. Prognosis of high risk NB is extremely poor. The
use of high-dose chemotherapy with autologous hematopoietic
stem cell rescue in consolidation has resulted in improvements in
survival and appears to have the largest impact on the survival of
the high risk subset of patients although long-term event-free sur-
vival remains less than 40–50%. The aim of this retrospective study
was to analyze the outcome of childrenwith high-risk neuroblastoma
who underwent Autologous Stem Cell Transplantation (ASCT) in
a new pediatric stem cell transplant facility.
Patients andMethods: Between August 2008 to July 2011, 16 chil-
dren underwent ASCT as part of a multimodality treatment ap-
proach consisted in induction chemotherapy, surgery, HDC and
autologous stem cell rescue, radiotherapy and maintenance therapy
with 13-cis retinoid acid. The conditioning regimen used in all cases
consisted of Carboplatin (375mg/m2 for 4 days), Etoposide (300mg
/m2 for 4 days), and Melphalan (60 mg/m2 for 3 days).
Results: There were 16 patients with NB consisting of 6 males and
10 females. The median age was 4.7 years (range 1-14 years). The
median weight was 17,4kg (range 8-40kg). 12 patients had stage
IV-NB and 4 had high-risk stage III-NB. The source of stem cells
was peripheral blood in 15 patients and bone marrow in 1 patient.
The median time to Absolute Neutrophil Count. 0.5 x 10 9/L
was 13 days (range 9-35 days). Themedian time to an Absolute plate-
let count of.20 x 10 9/L was 23 days (range 9-35 days), one patient
had a graft failure who presented adequate recovery after infusion of
cryopreserved bone marrow back-up. The median follow up time
was 492 days (range 55 days-1127 days). 4 of the 16 recipients had
relapsed. At the present time, 13 patients are alive. Relapse was the
only cause of death and Transplant Related Mortality was zero.
Conclusion: we conclude that ASCT is a feasible and effective
method of treatment for patients with high risk neuroblastoma.
The inclusion of high-dose chemotherapy and autologous rescue
have improved the chances of survival of children with high risk neu-
roblastoma in developing countries allowing to reproduce the results
achieved in developed countries.275
IMPACT OF NUTRITIONAL PARAMETERS ON OUTCOME AFTER PEDIAT-
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